Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge

Executive Summary

FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs

You may also be interested in...



FDA Oncology Therapeutics Office Will Contain Three Divisions

FDA's proposed oncology therapeutics office will be organized into three divisions, Center for Drug Evaluation & Research Medical Policy Director Robert Temple, MD, said June 17 during a Drug Information Association meeting in Washington, D.C

FDA Oncology Therapeutics Office Will Contain Three Divisions

FDA's proposed oncology therapeutics office will be organized into three divisions, Center for Drug Evaluation & Research Medical Policy Director Robert Temple, MD, said June 17 during a Drug Information Association meeting in Washington, D.C

CBER Oncology Group Will Work To Create Consistent Approach To Products

The Office of Cellular, Gene & Tissue Therapies' new oncology group will work to ensure coordination in approaches to oncology products throughout FDA

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel